grant
Alzheimer's Prevention Initiative ADAD Colombia Trial Program
NIHUS FederalResearch GrantFY2025AD dementiaAD preventionADAM10 proteinAddressAffectAgeAge YearsAgreementAlzheimer Type DementiaAlzheimer beta-ProteinAlzheimer disease dementiaAlzheimer disease preventionAlzheimer preventionAlzheimer sclerosisAlzheimer syndromeAlzheimer'sAlzheimer's Amyloid beta-ProteinAlzheimer's DiseaseAlzheimer's amyloidAlzheimers DementiaAmentiaAmyloidAmyloid (Aβ) plaquesAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid PlaquesAmyloid Protein A4Amyloid SubstanceAmyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAntibodiesAntibody TherapyAβBiologicalBiological MarkersBlood PlasmaBlood SampleBlood specimenBrainBrain Nervous SystemClinicalClinical TrialsCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCollaborationsColombiaColombianCombined Modality TherapyCommunity TrialDataDementiaDetectionDeveloping CountriesDeveloping NationsDevelopmentDisease ProgressionDisturbance in cognitionDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrug CombinationsDrugsEarly DiagnosisEncephalonEthicsFoundationsFundingFutureGuidelinesHuman ResourcesImageImpaired cognitionImpairmentIndividualInflammatoryInfrastructureInfusionInfusion proceduresInterventionIntervention StudiesInvestigationInvestigatorsInvestmentsLess-Developed CountriesLess-Developed NationsLigandsMR ImagingMR TomographyMRIMRIsMT-bound tauMagnetic Resonance ImagingManpowerMeasurableMeasurementMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceMedicationMentorsMultimodal TherapyMultimodal TreatmentNMR ImagingNMR TomographyNational Institutes of HealthNerve DegenerationNeuritic PlaquesNeuron DegenerationNuclear Magnetic Resonance ImagingOralPETPET ScanPET imagingPETSCANPETTPSEN1ParticipantPatientsPersonsPharmaceutical PreparationsPlacebo ControlPlacebosPlasmaPlasma SerumPopulationPositron Emission Tomography Medical ImagingPositron Emission Tomography ScanPositron-Emission TomographyPrevention ResearchPrevention therapyPrevention trialPrimary PreventionPrimary Senile Degenerative DementiaProductionRad.-PETRandomizedRegistriesResearch PersonnelResearchersResource SharingReticuloendothelial System, Serum, PlasmaRiskRoleS182 proteinSamplingSecondary PreventionSenile PlaquesSham TreatmentSocial supportTestingThird-World CountriesThird-World NationsUnder-Developed CountriesUnder-Developed NationsUnited States National Institutes of HealthVulnerable PopulationsZeugmatographya beta peptideabetaabeta accumulationabeta aggregationagesamyloid betaamyloid beta accumulationamyloid beta aggregationamyloid beta plaqueamyloid β accumulationamyloid β aggregationamyloid-b plaqueamyloid-b proteinantibody based therapiesantibody treatmentantibody-based therapeuticsantibody-based treatmentautosomal dominant ADautosomal dominant Alzheimer's diseaseaβ accumulationaβ aggregationaβ plaquesbeta amyloid fibrilbio-markersbiologicbiologic markerbiomarkerblindblood-based biomarkerblood-based markercarrier statusclinical effectcognitive assessmentcognitive dysfunctioncognitive losscognitive testingcombination therapycombined modality treatmentcombined treatmentcored plaquedata sharing networksdata sharing resourcedesigndesigningdetermine efficacydeveloping countrydeveloping nationdevelopmentaldiffuse plaquedrug/agentearly detectionearly onsetefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationethicalevaluate efficacyexamine efficacyexperiencegamma secretasegamma secretase compleximaginginfusionsinhibitorintervention effectintervention researchinterventional researchinterventional studyinterventions researchkindredmembermicrotubule bound taumicrotubule-bound taumulti-modal therapymulti-modal treatmentmutation carrierneural degenerationneurodegenerationneurodegenerativeneurological degenerationneuronal degenerationolder adultolder adulthoodpersonnelplacebo controlledplacebo grouppositron emission tomographic (PET) imagingpositron emission tomographic imagingpositron emitting tomographypre-clinicalpreclinicalpresenilin 1 proteinpresenilin-1preventpreventingprimary degenerative dementiaprogramsrandomisationrandomizationrandomly assignedrecruitsenile dementia of the Alzheimer typesham groupsham therapysocial rolesocial support networksoluble amyloid precursor proteintautau Proteinstau factortreatment groupvirtualvulnerable groupvulnerable individualvulnerable peopleγ-secretaseτ Proteins
Description preview
Project Summary/Abstract
When the API Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial (NCT01998841) was
announced in 2012, it launched a new era in AD prevention research. The trial led us to identify ~6,000 persons
from the world's largest ADAD kindred, including nearly 1,200 presenilin 1 (PSEN1) E280A mutation carriers,
who are…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click